Introduction:
Contract Development and Manufacturing Organisation (CDMO), Sterling Pharma Solutions is investing US$8 million into its pilot plant facility at its UK site.
Features:
The facility will enhance the pilot plant’s capacity by 33 per cent and increase the site’s production capabilities and flexibility for small to mid-scale batch production.
Three new reactor trains at scales of 225L, 500L, and 1, 360L will be added at the cGMP facility. The facility is expected to be operational by mid-2018.
These reactors will help to meet the growing demands for API batch sizes in the 10-100 kg range and will balance the CDMO’s API full service offering and current scale-up capabilities from grams to tonnes.
The 40-acre site will also add a range of new capabilities to expand the ability to handle potent compounds across a range of equipment scales.
The expansion follows an investment in 2017 into the site’s milling, micronisation, and solid form facility.
Both investments form part of a strategic development plan totaling almost US$16 million.
Specifications:
| Name | Sterling Pharma Solutions |
| Location | Dudley, North Tyneside, England |
| Type | Expansion |
| Estimated Budget | US$8 million |
| Parties Involved | Sterling Pharma Solutions |
| Schedule | Scheduled to be operational by mid- 2018 |
